ATE402150T1 - Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen - Google Patents

Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen

Info

Publication number: ATE402150T1
Authority: AT; Austria
Prior art keywords: compounds; pyrazolamine; treatment; neurodegenerative diseases; formula
Prior art date: 2004-04-01

Application number

AT05708792T

Other languages

English (en)

Inventor

Yuhpyng Chen

Lei Zhang

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-01

Filing date

2005-03-21

Publication date

2008-08-15

2005-03-21 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE402150T1 publication Critical patent/ATE402150T1/de

Links

208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000000626 neurodegenerative effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT05708792T 2004-04-01 2005-03-21 Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen ATE402150T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US55890404P	2004-04-01	2004-04-01

Publications (1)

Publication Number	Publication Date
ATE402150T1 true ATE402150T1 (de)	2008-08-15

Family

ID=34962302

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05708792T ATE402150T1 (de)	2004-04-01	2005-03-21	Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen

Country Status (10)

Country	Link
US (2)	US7244757B2 (de)
EP (2)	EP1958939A3 (de)
JP (1)	JP2007530659A (de)
AT (1)	ATE402150T1 (de)
BR (1)	BRPI0509559A (de)
CA (1)	CA2561441A1 (de)
DE (1)	DE602005008417D1 (de)
ES (1)	ES2308442T3 (de)
MX (1)	MXPA06011351A (de)
WO (1)	WO2005095348A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7763609B2 (en)	2003-12-15	2010-07-27	Schering Corporation	Heterocyclic aspartyl protease inhibitors
US7244757B2 (en) *	2004-04-01	2007-07-17	Pfizer Inc	Pyrazole-amine compounds for the treatment of neurodegenerative disorders
US7923465B2 (en) *	2005-06-02	2011-04-12	Glenmark Pharmaceuticals S.A.	Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
FR2913886B1 (fr)	2007-03-22	2012-03-02	Guerbet Sa	Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
US9828344B2 (en)	2012-06-01	2017-11-28	LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG FRITZ-LIPMANN-INSTITUT e.V. (FLI)	Inhibitors of the notch signaling pathway and secretion for use in medicine
SG11201602572YA (en)	2013-10-03	2016-04-28	Kura Oncology Inc	Inhibitors of erk and methods of use
WO2019161162A1 (en) *	2018-02-16	2019-08-22	Constellation Pharmaceuticals, Inc.	P300/cbp hat inhibitors
EP4003342A1 (de) *	2019-07-29	2022-06-01	Constellation Pharmaceuticals, Inc.	Verbindungen zur verwendung bei der behandlung von neurologischen erkrankungen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS503340Y2 (de) *	1971-06-17	1975-01-28
US6387900B1 (en)	1999-08-12	2002-05-14	Pharmacia & Upjohn S.P.A.	3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
NZ523656A (en)	2000-08-31	2004-11-26	Pfizer Prod Inc	Pyrazole derivatives and their use as protein kinase inhibitors
AU2002215053A1 (en)	2000-11-27	2002-06-24	Pharmacia Italia S.P.A.	Phenylacetamido- pyrazole derivatives and their use as antitumor agents
US7053220B2 (en)	2002-02-01	2006-05-30	Elan Pharmaceuticals, Inc.	Hydroxyalkanoyl aminopyrazoles and related compounds
AU2003229024A1 (en)	2002-05-07	2003-11-11	Elan Pharmaceuticals, Inc.	Succinoyl aminopyrazoles and related compounds
MXPA05003432A (es)	2002-10-09	2005-07-05	Pfizer Prod Inc	Compuestos pirazoles para el tratamiento de trastornos neurodegenerativos.
MXPA05012196A (es)	2003-05-12	2006-02-08	Pfizer Prod Inc	Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
JP4220548B2 (ja) *	2003-06-05	2009-02-04	エランファーマシューティカルズ，インコーポレイテッド	アシル化されたアミノ酸・アミジルピラゾール、および関連化合物
US7244757B2 (en) *	2004-04-01	2007-07-17	Pfizer Inc	Pyrazole-amine compounds for the treatment of neurodegenerative disorders

2005
- 2005-03-11 US US11/078,861 patent/US7244757B2/en not_active Expired - Fee Related
- 2005-03-21 EP EP08157177A patent/EP1958939A3/de not_active Withdrawn
- 2005-03-21 WO PCT/IB2005/000793 patent/WO2005095348A2/en not_active Ceased
- 2005-03-21 MX MXPA06011351A patent/MXPA06011351A/es active IP Right Grant
- 2005-03-21 JP JP2007505655A patent/JP2007530659A/ja not_active Withdrawn
- 2005-03-21 ES ES05708792T patent/ES2308442T3/es not_active Expired - Lifetime
- 2005-03-21 EP EP05708792A patent/EP1735285B1/de not_active Expired - Lifetime
- 2005-03-21 AT AT05708792T patent/ATE402150T1/de not_active IP Right Cessation
- 2005-03-21 DE DE602005008417T patent/DE602005008417D1/de not_active Expired - Fee Related
- 2005-03-21 CA CA002561441A patent/CA2561441A1/en not_active Abandoned
- 2005-03-21 BR BRPI0509559-0A patent/BRPI0509559A/pt not_active IP Right Cessation
2007
- 2007-07-05 US US11/773,831 patent/US7468386B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1958939A3 (de)	2008-09-10
EP1735285B1 (de)	2008-07-23
US20050222239A1 (en)	2005-10-06
WO2005095348A3 (en)	2006-03-23
US7468386B2 (en)	2008-12-23
WO2005095348A2 (en)	2005-10-13
JP2007530659A (ja)	2007-11-01
MXPA06011351A (es)	2006-12-15
CA2561441A1 (en)	2005-10-13
ES2308442T3 (es)	2008-12-01
EP1735285A2 (de)	2006-12-27
US20070265327A1 (en)	2007-11-15
US7244757B2 (en)	2007-07-17
EP1958939A2 (de)	2008-08-20
DE602005008417D1 (de)	2008-09-04
BRPI0509559A (pt)	2007-09-18

Legal Events

Date	Code	Title	Description
2009-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
UA83899C2 (uk)	2008-08-26	Сполуки імідазолу для лікування нейродегенеративних розладів
TW200420550A (en)	2004-10-16	Thiazole compounds for the treatment of neurodegenerative disorders
BR0315158A (pt)	2005-08-16	Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
CA2534532A1 (en)	2005-03-10	Compounds for the treatment of neurodegenerative disorders
MXPA05012196A (es)	2006-02-08	Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
BRPI0509504A (pt)	2007-09-11	compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos
MY136718A (en)	2008-11-28	Sulfonamide compounds for the treatment of neurodegenerative disorders
ATE402150T1 (de)	2008-08-15	Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
TW200510351A (en)	2005-03-16	Oxazole compounds for the treatment of neurodegenerative disorders
CR9815A (es)	2008-04-16	Compuestos de imidazol para el tratamiento de transtornos neurologicos
WO2005097114A3 (en)	2006-08-24	Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
ATE399758T1 (de)	2008-07-15	Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
WO2005095361A8 (en)	2006-08-03	Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders
BRPI0509582A (pt)	2007-10-09	compostos de tiazol-amina e respectivas composições farmacêuticas
MY145068A (en)	2011-12-15	Imidazole compounds for the treatment of neurodegenerative disorders
DOP2004000982A (es)	2005-02-28	Compuestos para el tratamiento de trastornos neurodegenerativos
DOP2006000200A (es)	2007-03-31	Compuestos de imidazol para el tratamiento de trastonos neurologicos
EA200500382A1 (ru)	2005-08-25	Соединения тиазола для лечения нейродегенеративных расстройств
CU23591B7 (es)	2010-10-30	Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos
BRPI0402756A (pt)	2006-02-21	método para o tratamento de distúrbios cognitivos